Serum Parathyroid Hormone, 25-Hydroxyvitamin D, and Risk of Alzheimer's Disease: A Mendelian Randomization Study

Nutrients. 2018 Sep 6;10(9):1243. doi: 10.3390/nu10091243.

Abstract

We conducted Mendelian randomization analyses to investigate the associations of serum parathyroid hormone (S-PTH) and serum 25-hydroxyvitamin D (S-25OHD) concentrations with Alzheimer's disease (AD). Five and seven single nucleotide polymorphisms associated with S-PTH and S-25OHD concentrations, respectively, were used as instrumental variables. Data for AD were acquired from the International Genomics of Alzheimer's Project (17,008 AD cases and 37,154 controls). Genetically higher S-PTH concentrations were not associated with AD (odds ratio per standard deviation increase in S-PTH = 1.11; 95% CI 0.97⁻1.26; p = 0.12). In contrast, all seven 25OHD-increasing alleles were inversely associated with AD and two of the associations were statistically significant (p < 0.05). The odds ratio of AD per genetically-predicted one standard deviation increase in S-25OHD was 0.86 (95% CI 0.78⁻0.94; p = 0.002). This study provides evidence that vitamin D may play a role in AD but found no significant association between S-PTH and AD.

Keywords: Alzheimer’s disease; Mendelian randomization; parathyroid hormone; vitamin D.

MeSH terms

  • Alzheimer Disease / blood
  • Alzheimer Disease / diagnosis
  • Alzheimer Disease / genetics*
  • Alzheimer Disease / prevention & control
  • Biomarkers / blood
  • Case-Control Studies
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study
  • Humans
  • Mendelian Randomization Analysis
  • Parathyroid Hormone / blood*
  • Phenotype
  • Polymorphism, Single Nucleotide*
  • Protective Factors
  • Risk Factors
  • Vitamin D / analogs & derivatives*
  • Vitamin D / blood

Substances

  • Biomarkers
  • PTH protein, human
  • Parathyroid Hormone
  • Vitamin D
  • 25-hydroxyvitamin D

Grants and funding